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ABSTRACT
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD),
where prolonged exposure to hyperglycemia induces damage to proximal tubule cells of
the kidney. Since progression to ESRD correlates to pathological changes in the tubular
segments of the kidney, the effects of hyperglycemia in the PT portion of the nephron
may be particularly relevant to the progression of DN. Development of this disease also
is likely to occur in the context of exposure to other renal toxins, and the heavy metal
cadmium (Cd2+) may be the most relevant due to the accumulation of this metal in the
major cell type involved in glucose reabsorption: proximal tubule cells. Preliminary
microarray analysis has shown human proximal tubule (HPT) cells exposed acutely and
chronically to Cd2+ have an increased expression of an aldose reductase (AR) isoform,
AKR1B10. This isoform along with AKR1B1 and sorbitol dehydrogenase (SORD) are
involved in glucose metabolism under hyperglycemic conditions via the polyol pathway.
The goal of this study was to verify and extend these observations in culture of HPT
cells. For this purpose, HPT cells were exposed to one of the three following treatments;
5.5 (control), 7.5, 11, or 16 mM glucose concentrations for 8 days; 9, 27, 45 μM Cd2+ for
24 hours (acute), or 4.5, 9, 27 μM Cd2+ for 13 days (chronic). Real-time PCR was used to
measure the expression level of these enzymes. Exposures to either hyperglycemia or
Cd2+ stimulated a significant induction of AKR1B10 in HPT cells; however, exposure to
xii

these renal toxins had no effect on AKR1B1 or SORD expression. We also observed
glucose-induced loss of epithelial morphology that correlated to an induction of NCadherin (CDH2), a mesenchymal marker. These results are suggestive of potential
synergistic effects of Cd2+ and hyperglycemia in the toxic responses of the proximal
tubules during the development of DN.

xiii

CHAPTER I.I
INTRODUCTION
Impact
Diabetes mellitus is one of the most prevailing pathologies in today’s society
affecting more than 25.8 million people in the United States, making it the 7th leading
cause of death (American Diabetes Association; Yu & Bonventre, 2018). Diabetes
mellitus is characterized by chronic hyperglycemia and microvascular complications in
the renal glomerulus (nephropathy), retina (retinopathy), peripheral nerve (neuropathy)
(M Brownlee, 2001; Sheetz & King, 2002). Diabetes mellitus is a complicated disease
that affects not only the kidneys but is also known to induce vascular problems in other
regions of the body that can lead to limb amputations, cardiovascular disease, blindness,
etc. ( American Diabetes Association ; Das & Srivastava, 1985). A high interest in
mechanistic research into diabetes mellitus is sparked by the awareness of the health
problems associated with this disease.
Diabetic nephropathy (DN) is one of the most serious complications of diabetes
mellitus (Edwards & Prozialeck, 2009; Suarez, Thomas, Barisoni, & Fornoni, 2013;
Tervaert et al., 2010). Diabetic nephropathy is a microvascular disease where prolonged
exposure to hyperglycemia induces damage to various cells of the kidney, ultimately
developing into chronic kidney disease (CKD) (Kanwar, Sun, Xie, Liu, & Chen, 2011).
Some of the renal morphological changes that occur in diabetic nephropathy are
1

basement membrane thickness, accumulation of extracellular matrix proteins, glomerular
and renal hypertrophy, fibrosis, a decline in glomerular filtration rate, etc. (Kanwar et al.,
2011; Macisaac, Ekinci, & Jerums, 2014; Schrijvers, De Vriese, & Flyvbjerg, 2004).
Once there is a detection of proteinuria, end-stage renal disease quickly follows. The
mechanism(s) of diabetic nephropathy are highly complicated and poorly understood,
making the disease more difficult to treat.
Some known risk factors that contribute to diabetic nephropathy have been
identified such as hyperglycemia and diet. Exposure to prolonged hyperglycemic
conditions can have detrimental effects on the kidney by activating metabolic and
signaling pathways where downstream targets result in morphological and functional
changes. These detrimental effects can lead to acute kidney injury and if not treated it can
progress into a more damaging and irreversible state. Although there are several known
contributing risk factors for diabetic nephropathy, there still may be unidentified
environmental factors that can make an individual more susceptible to hyperglycemic
damage or cause the disease to progress into a more advanced, damaging state.
With regards to environmental factors, there is a growing body of evidence to
support Cd2+ exposure contributes to the development of chronic kidney disease but also
increases the severity of hyperglycemic damage on the kidneys (Edwards & Prozialeck,
2009; Gobe & Crane, 2010; Klaassen, Liu, & Diwan, 2009; Prozialeck & Edwards, 2012;
Thévenod, 2003). Therefore to properly understand diabetic nephropathy and the
2

mechanisms behind the disease progression, it’s important to understand how these
toxicants induce irreversible damage in diabetic nephropathy. Also, understanding the
pathological mechanisms behind diabetic nephropathy can provide health professionals
the means for an early detection and prevention of the disease, as well as its progression.
Acute and Chronic Kidney Disease
Development of kidney diseases can occur rapidly (acute) or over long periods of
time (chronic). Acute kidney injury is a reversible, sudden, rapid loss of the kidneys’
excretory functions that is clinically seen by the accumulation of urea (BUN) or
creatinine in the blood, decreased urine output, or a combination of both which normally
dissipates within a week of initial diagnosis (Basile, Anderson, & Sutton, 2012; Bellomo,
Kellum, & Ronco, 2012; Levey, Levin, & Kellum, 2013). Acute kidney injury is caused
by several independent events such as dehydration, surgery, use of medicines, or
overnight hospital stays (Chawla, Eggers, Star, & Kimmel, 2014). Although acute kidney
injury is an independent disease, however if there is not a full recovery from the acute
kidney injury it will make the patient more susceptible to disease progression to chronic
kidney disease.
Chronic kidney disease is defined as an irreversible, gradual loss of the kidneys’
excretory functions with the presence of kidney damage (i.e. albuminuria) which is
evident for three months or longer (Levey & Coresh, 2012). Renal damage that is
associated with chronic kidney disease is caused by the loss of viable nephrons.
Researchers have intensely studied glomerular damage in chronic kidney disease
3

research, because not only is this the site of glomerular filtration, but also glomerular
damage is a characteristic of chronic disease. However recent studies have suggested
tubular damage is also a hallmark of chronic kidney disease and an indicator of disease
progression and severity (Han, Ly, Tesch, Poronnik, & Nikolic-Paterson, 2018;
Schelling, 2016).
The presence of albumin in the urine is a hallmark of both acute and chronic
kidney disease and can be used to determine if the state of the disease will progress to
end-stage kidney disease (Astor et al., 2011; Looker et al., 2015). Early stages of chronic
kidney disease show an increase of albuminuria and a decreased glomerular filtration rate
(GFR) (Coresh, Astor, Greene, Eknoyan, & Levey, 2003) whereas evidence of
glomerulosclerosis and renal interstitial fibrosis is an indication of severe chronic kidney
disease that leads to end-stage renal disease (T. Lee, Shah, Leonard, Parikh, & Thakar,
2018). In cases of evident glomerulosclerosis, there is an increase of endothelial damage
and dysfunction, activation and proliferation of smooth muscle or mesangial cells, and
injury to the podocytes (A Meguid El Nahas & Bello, 2005). Communication between
cells via cytokines or growth factors leads to the increased deposition of extracellular
matrix that leads to scarring of the glomerulus.
Damage to the proximal tubules is also seen in chronic kidney disease. Damage to
the proximal tubules is independent of the damage that occurs in the glomerulus. The
proximal tubules are subjected to irreversible damage and undergo morphologic changes,
such as loss of brush border and apical mitochondria followed by complete loss of tubular
4

epithelial cells, or whole tubules that occurs with interstitial fibrosis (Risdon, Sloper, &
De Wardener, 1968; Rosenbaum, Mikail, & Wiedmann, 1967; Schelling, 2016).
As scientists are becoming more aware of the damaging effects that are associated
with chronic kidney disease, there is not only a growing need to investigate the
complications associated with this disease to find a treatment to halt the disease
progression but also because of the increased incidence of patients inflicted with chronic
kidney disease.
The number of patients diagnosed with chronic kidney disease is growing at an
alarming rate and is a major concern for not only health-care professionals but also the
diagnosed individuals and their care-takers. Due to the fact of the development of chronic
kidney disease in diabetic patients significantly increases the mortality and morbidity
rates along with health care costs world- wide (Roshan & Stanton, 2013). The health care
costs are incurred to detect and manage chronic kidney disease, end-stage renal disease,
and simultaneous management of comorbid conditions such as diabetes, congestive heart
failure, and hypertension (V. Wang, Vilme, Maciejewski, & Boulware, 2016).
Epidemiologically, there are several causes of chronic kidney disease with diabetes
mellitus being the greatest contributor(Thakar, Christianson, Himmelfarb, & Leonard,
2011). Although diabetes mellitus is heavily studied, the mechanism(s) behind the
disease progression to a chronic kidney disease and ultimately end-stage renal disease
(ESRD) remains least understood.

5

Diabetic Nephropathy
Diabetic nephropathy is a serious microvascular complication of diabetes mellitus
and is the leading cause of chronic kidney disease (Kanwar et al., 2011; Suarez et al.,
2013; Tervaert et al., 2010). Diabetic nephropathy is characterized by the early detection
of albuminuria after diagnosis of diabetes mellitus (Suarez et al., 2013). However
pathophysiological changes occur after prolonged exposure, such as hypertrophied
glomeruli and tubules that is associated with increased thickening of the glomerular and
tubular basement membranes that results from the excessive deposition of extracellular
matrix (ECM) (Fioretto & Mauer, 2007; Kanwar et al., 2011). Renal injuries that arise
from diabetes mellitus whether its type 1 or type 2 result in a similar pathophysiological
outcome (Fioretto & Mauer, 2007). Diabetic nephropathy is caused by prolonged
exposure to hyperglycemia.

Glucose Handling by Proximal Tubule Cells
The kidney’s main function is to reabsorb and transport nutrients from the
glomerular filtrate back into the blood to be used by other systems. Since the proximal
tubule cells are responsible for reabsorbing roughly 90% of the nutrients such as glucose,
amino acids, or salts in the ultra-filtrate, it’s important to understand how these cells
respond to an increased level of glucose.
The proximal tubule cell reabsorbs glucose via two mechanisms; sodium-glucose
linked transporter (SGLT) and facilitated glucose transporter (GLUT) (Blantz & Singh,
6

2014; Y. J. Lee, Lee, & Han, 2007; Vallon & Thomson, 2012). Sodium-glucose linked
transporter transports glucose in an insulin independent manner and is driven by a highflux low-affinity of glucose at the brush border of the apical membrane (Mather &
Pollock, 2011). Facilitated glucose transporters are found at the apical and basolateral
regions of the cell and can bi-directionally transport glucose across the cell membrane (Y.
J. Lee et al., 2007) Similar to SGLTs, GLUTs are driven by the high-flux low affinity of
glucose (Alsahli & Gerich, 2017; Y. J. Lee et al., 2007). Since the transport of glucose is
insulin-independent, the proximal tubule cells are more susceptible to damage caused by
high levels glucose, hyperglycemia.
When glucose in the filtrate reaches approximately 10 mmol/L, the SGLTs and
GLUTs become saturated and the maximal reabsorption rate has been met (Poudel,
2013). Under these conditions, glucose in the urine can be detected. If the problem
persists, damage to the proximal tubule cells will occur.
Mechanisms of Hyperglycemia Damage in Proximal Tubule Cells
There are several hypothesis of hyperglycemia induced damaged that have been
intensely studied, as well been the main focus in clinical trials. There are several
hypotheses about the mechanism as to how complications associated with diabetic
nephropathy arise. One possible mechanism, activation of the polyol pathway, was shown
to be the major player in complications associated with diabetic retinopathy (VAN
HEYNINGEN, 1959). Several studies following the initial discovery of the role of the
polyol pathway’s involvement in cataract formation in diabetic retinopathy have targeted
7

aldose reductase activity as a means of treatment. Since microvascular complications
induced by diabetes mellitus are pathophysiologically similar in the retina and kidney,
investigation into how activation of the polyol pathway leads to complications in diabetic
nephropathy has been intensely studied (Das & Srivastava, 1985; Fowler, 2008).
Once inside the proximal tubule cell, glucose can be metabolized by two different
enzymes 1) hexokinase to form glucose-6-phosphate or 2) aldose reductase (ARK1B1) to
form sorbitol (Kinoshita, 1990; Yabe-Nishimura, 1998). However hexokinase will
become saturated as the glucose influx increases rendering aldose reductase the main
means of glucose metabolism. This increased activity of aldose reductase leads to
complications such as osmotic and oxidative stress (Michael Brownlee, 2005).
Aldose reductase is the first and rate-limiting enzyme of the polyol pathway
(Hodgkinson et al., 2001). Aldose reductase belongs to a family of NADPH
oxidoreductases where there are three isoforms of the AKR1B in humans; AKR1B1,
AKR1B10, and AKR1B15 (Cao, Fan, & Chung, 1998; Giménez-Dejoz et al., 2017;
Taskoparan et al., 2017). Aldose reductase is a cytosolic, monomeric NAPDH-dependent
oxidoreductase that metabolizes a wide variety of carbonyl molecules such as sugars,
aldehyde metabolites, and ketones (Bohren, Bullock, Wermuth, & Gabbay, 1989). These
enzymes are more efficient at reducing aromatic and aliphatic aldehydes but in
hyperglycemic conditions will metabolize glucose to sorbitol (Cao et al., 1998; Zopf et
al., 2009). Sorbitol dehydrogenase (SORD) is the second enzyme of the polyol pathway
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and it oxidizes sorbitol to fructose using NAD+ as a cofactor (Gabbay, 1973; Schrijvers
et al., 2004).

Figure 1.1 Polyol Pathway. Adapted from (Brownlee. 2004).

Evidence for the Role of the Polyol Pathway in Diabetic Complications
Since sorbitol is unable to freely cross the cell membrane it accumulates within
the cell leading to complications associated with microvascular diseases such as osmotic
damage. The role of aldose reductase isoform, AKR1B1, in microvascular complications
with diabetes was first found out in the mid- 1950’s. The early work of Dr. Van
Heyningen set the stage of the role of the polyol pathway in microvascular complications
associated with diabetes.
In 1974, a group from London was trying to determine why genetically diabetic
mice did not experience cataracts. It was concluded that these mice (and several other
mice of different backgrounds) had a low level of aldose reductase activity in the lens,
but when the activity was looked at in rats, there was an appreciable high amount of
aldose reductase activity in a diabetic state (Varma, Mikuni, & Kinoshita, 1975),
suggesting these rats experienced cataract formation when they were clinically diagnosed
9

as having diabetes. After several years of intensive investigations, researchers concluded
the polyol pathway activation has some role in the onset of complications associated with
hyperglycemia, the generations of inhibitors targeted at aldose reductase were in popular
demand.
However it wouldn’t be until a decade later that researchers studied the role of the
polyol pathway in complications associated with diabetic nephropathy. Researchers
concluded in diabetic induced mice treated with an aldose reductase inhibitor showed
decreased levels of proteinuria (Beyer-Mears, Ku, & Cohen, n.d.; Cohen, 1986). These
studies were the first to relate complications of diabetic nephropathy with activation of
the polyol pathway.
Shortly after Beyer-Mears study, another study looked directly at human proximal
tubule cells response to hyperglycemia and if the polyol pathway was involved. This
group of researchers concluded that human proximal tubule cells exposed to high levels
of glucose (27.5 mM) for short periods of time had an increased accumulation of sorbitol
and increased aldose reductase activity while no change in sorbitol dehydrogenase
activity (Bylander & Sens, 1990). When the cells were treated with an aldose reductase
inhibitor, sorbinil, there were diminished levels of sorbitol accumulation and aldose
reductase activity suggesting the polyol pathway has a role in complications associated
with diabetic nephropathy via intracellular accumulation of sorbitol.
Since then there have been several studies supporting aldose reductase increased
activation in hyperglycemic conditions and its role in diabetic mellitus complications
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(Hodgkinson et al., 2001; Rusak, Misztal, Rusak, Branska-Januszewska, & Tomasiak,
2017; Shah, Dorin, Sun, Braun, & Zager, 1997; Shukla, Pal, Sonowal, Srivastava, &
Ramana, 2017).
At the time of the initial studies of the polyol pathway and hyperglycemia, little
was known about the polyol pathway enzymes and their roles in diabetic complications.
Researchers knew the production of sorbitol was a driving force for microvascular
complications in diabetes and when aldose reductase activity was inhibited complicated
ceased. Since these first investigations, there have been several other aldose reductase
isoforms discovered. However, their roles in diabetic complications are least understood.
While the biological role of AKR1B10 is unknown however it has been shown to
be involved in a wide variety of metabolic pathways such as retinoic acid (Gallego et al.,
2006) and is over expressed in several different types of cancer such as breast,
endometrial, and or lung (Huang et al., 2016; Reddy et al., 2017).
In 2014, the first study to investigate AKR1B10 involvement in complications of
diabetes nephropathy was published. These researchers investigated the role of
AKR1B10 in patients with type 1 diabetes mellitus but no signs of nephropathy, versus
type 1diabetics with nephropathy, and healthy with no signs of type 1 or 2 diabetes.
Under high glucose (20 mM) conditions there was a significant induction of AKR1B10
protein levels in samples collected from patients with diabetic nephropathy in comparison
to no induction in samples collected from healthy patients (Shaw, Yang, Millward,
Demaine, & Hodgkinson, 2014).
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Although the work by Shaw et al., 2014 were the first to demonstrate AKR1B10
is induced by high glucose; no further research has been conducted on this enzyme’s
expression in the kidney of diabetic nephropathy.
Treatment for Diabetic Nephropathy
In the initial discovery of aldose reductase in the microvascular complications
associated with diabetes mellitus, there was a mass generation of inhibitors as a possible
treatment. These inhibitors were either the competitive or noncompetitive type. Initial
studies on aldose reductase biological properties demonstrated it was sensitive to longchain fatty acids which led to the development of the first aldose reductase inhibitor, 3,3tetramethyleneglutaric acid (TMG) (Jedziniak & Kinoshita, 1971). TMG was shown to
inhibit aldose reductase in diabetic-induced rat lens and in the process cataract formation
decreased. A couple years following, the establishment of a more potent aldose reductase
inhibitor was produced; alrestatin (Gabbay, Spack, Loo, Hirsch, & Ackil, 1979) In 1981,
the first clinical trial was conducted with diabetic neuropathy patients but was halted due
to toxic effects of the inhibitor (Tsai & Burnakis, 1993).
Several aldose reductase inhibitors have been produced and have shown to be an
effective treatment in improving the complications of diabetes mellitus however due to
adverse side-effects in clinical trials all but one aldose reductase inhibitor were
discontinued from further trials. Epalrestat is the only aldose reductase inhibitor currently
commercially available for treating complications associated with diabetes mellitus
((Grewal, Bhardwaj, Pandita, Lather, & Sekhon, 2016).
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Other Contributing Factors and Diabetic Nephropathy
There are several risk factors that can lead to the disease progression of diabetes
to diabetic nephropathy such as lifestyle, genetics, and environmental factors. Although
several risk factors have been identified as playing a role in the disease progression to
diabetic nephropathy, there are still several unidentified environmental risk factors that
may also play a role in this disease progression. Up until recently, there has been more
support that cadmium may have a role in the disease progression of diabetes to diabetic
nephropathy.
Cadmium Toxicity Causes Proximal Tubule Cell Damage
Cadmium is a heavy metal toxicant found naturally in the environment where
exposures cause serious health effects in those exposed. This is a growing concern for
those in the medical fields, government agencies, and the public since exposure can occur
through several sources including diet and habit, burning of fossil fuels, and industrial
mining to name a few (ASTDR). Individuals who smoke cigarettes obtain the majority of
their cadmium exposure via tobacco smoke as this route of entry leads to an efficient
absorption from the lungs, however the lungs are not the only site of Cd2+ insult (Garrett,
Somji, Sens, Zhang, & Sens, 2011). Cadmium toxicity has also been shown to cause
damaging effects in the skeletal system and kidneys.
Sources of Cadmium Exposure
The general population is exposed to Cd2+ through three main sources; tobacco,
food, and occupation. Cadmium exposure through inhalation of tobacco smoke occurs
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because cadmium accumulates in the tobacco plant, Nicotiana tabacum and it generates
levels of .5 to 2 μg of Cd2+ per cigarette (Ganguly, Levänen, Palmberg, Åkesson, &
Lindén, 2018). Cadmium through this route of entry is in the form of cadmium oxide
where it can be deposited in the lung tissue or absorbed into the systemic blood
circulation. (Yue, 1992).
Contaminated soil is the main source of Cd2+ exposure in the population of nonsmokers. Agricultural and industrial activities have contributed to the alarming increase
of contaminated soil. Therefore whole grains, leafy vegetables, root vegetables and some
seeds contain high amounts Cd2+ and account for 80% dietary source (Ganguly et al.,
2018).
The final source of Cd2+ toxicity is through occupational exposure. This typically
occurs in industrial factories such as smelters, battery manufacturing, metal recovery
factories, or production units for paint and pigment (Nair, DeGheselle, Smeets, Van
Kerkhove, & Cuypers, 2013).
As researchers and health officials recognize the possible effects Cd2+ toxicity can
have on the human body, the more researchers have studied the damaging effects of this
toxicant.
Potential Mechanisms for Cadmium Cellular Damage
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Cadmium enters the body through the lungs or the gastrointestinal tract through
tobacco smoke or food intake, respectively. Although the exact mechanism which cells
uptake Cd2+ is unknown, it has been theorized that Cd2+uses similar transport systems as
other metals such as calcium, iron, zinc, and manganese due to their similar size
(Clarkson, 1993; Satarug, 2018). These transport systems include divalent metal
transporter 1 (DMT1), ZIP8, and ZIP14 (Girijashanker et al., 2008; Park, Cherrington, &
Klaassen, 2002). However, if there is a restriction of iron, zinc, or calcium then this will
lead to a greater absorption and accumulation of Cd2+ (Vesey, 2010), therefore nutritional
state must be taken into consideration when studying the effects of Cd2+ toxicity and
transport.
Once Cd2+ is absorbed it binds to high molecular weight proteins in the blood and
is transported to the liver where it binds to and stimulates metallothionein synthesis
(Järup, Berglund, Elinder, Nordberg, & Vahter, 1998). Metallothioneins are low
molecular weight proteins that are widely distributed in the body. These proteins have a
high cysteine content which allows them to have a high affinity for metals such as zinc,
cadmium, mercury, copper, lead, and iron (Klaassen et al., 2009; Sabath & RoblesOsorio, 2012) Although these metals have the capability of binding to metallothioneins,
when Cd2+ is present it will displace other metals and bind to metallothioneins.
After Cd2+ is bound to the metallothionein proteins, it is then transported back
into blood where it is filtered by glomerulus and reabsorbed by proximal tubule cells of
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the kidney. Expression of ZIP8 transporters at the apical membrane mediates the uptake
of Cd2+ bound metallothionein complexes (Fujishiro, Yano, Takada, Tanihara, &
Himeno, 2012; Satarug, 2018; Schneider et al., 2014). Another possible mechanism of
transport of Cd2+ bound metallothionein complexes into the kidney is by megalin whereas
megalin mediates uptake of Cd2+ bound metallothionein via endocytosis (Wolff,
Abouhamed, Verroust, & Thévenod, 2006). After the Cd2+ bound metallothionein
complexes are within the cell, they are degraded by endosomal and lysosomal
mechanisms with the release of Cd2+causing programmed cell death. Since Cd2+ has a
half-life of 10 – 30 years (Friberg, 1984; Järup et al., 2000) it easily accumulates within
the proximal tubule cells rendering it more susceptible to cadmium toxicity (Edwards &
Prozialeck, 2009).
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The proximal tubule cells have a Cd2+ threshold of 150- 200 ug/g, exposure to
anything of above these levels leads to polyuria, proteinuria and glucosuria (Järup et al.,
2000; Satarug, Haswell-Elkins, & Moore, 2000). As Cd2+ overloads the proximal tubule
cells system, it can exert its toxic effects by activating pathways of the inflammatory
response, oxidative stress, and genotoxicity.

Figure 1.2 Schematic diagram of Cd2+ uptake, transport and urinary excretion.
Adapted from (Satarug S. 2018).

The first evidence of Cd2+ toxicity arose in 1955 in Japan where residents were
exposed to low concentrations of Cd2+ through ingestion of contaminated rice developed
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an outbreak of Itai-Itai disease, which translates to “it hurts – it hurts”. These exposed
individuals were found to have renal tubular damage, osteomalacia, anemia and
malabsorption (Nordberg, 2009). In another study, conducted specifically on middle-aged
women in Sweden, found a connection between Cd2+ accumulation and renal injury. In
this study the maximal Cd2+ accumulation individuals experienced, impaired tubular
reabsorption, as evident by the presence of proximal tubule proteins in urine i.e. N-acetylβ-D-glucosaminidase (Akesson et al., 2005).
Due to the health risks associated with Cd2+ exposure, regulations were created to
prevent and monitor excessive toxicant contamination and exposure.
Regulation of Cadmium Exposure
As the toxic effects of Cd2+ exposure are becoming more evident, guidelines were
established by federal health agencies. Occupational safety and health administration
(OSHA) established set limits of Cd2+ exposure in the workplace. According to their
guidelines, the permissible exposure limit is 5 μg/ m3 and National Institute of
Occupational Safety and Health (NIOSH) has set an immediately dangerous to life and
health level (IDLH) of 9mg/m3 (OSHA, 2012; NIOSH; 2012).
Cadmium exposure standards have also been set to protect the general population
by several different government agencies. The U.S. Food and Drug Administration
(FDA) has a set a .0005 mg/L of Cd2+ in bottled water, ASTDR has a set Cd2+ intake of
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.1 μg/kg/day, EPA has set a Cd2+ dose from food at .001 mg/kg/day and .0005 mg/kg/day
from water (ASTDR, 2013).
When regulations fail to exist for toxicants that are known to have adverse health
effects, it can lead major health problems in the general population.
Cadmium and Diabetic Nephropathy
Evidence suggests early Cd2+ exposure may have a contributing factor to the onset
and severity of diabetes mellitus. Although, there is contradictory evidence of the
relationship between cadmium exposure and the risk of developing diabetes mellitus.
Studies have shown elevated cadmium exposure was associated with a higher
BMI, waist, and hip circumference in teenage females (Kim et al., 2015). These findings
were supported by a study conducted on the indigenous people of the Torres Strait
Islands. 32% of women between the ages of 30 and 50 had detectable levels of cadmium
in their urine, 2 µg of cadmium per gram of creatinine (Haswell-Elkins et al., 2007)
where normal levels are .26 µg of cadmium per gram of creatinine (ATSDR, 2013).
In 2003, Schwartz et al. analyzed data from the National Health and Nutrition
Examination Survey (NHANES) III (1988-1994) that involved 8772 adults, had shown
increasing urinary cadmium levels were associated with an impaired fasting glucose
(defined by ≥100 and < 126 mg/dl) and increased prevalence of type II diabetes
(Schwartz, Il’yasova, & Ivanova, 2003).
Similarly, Wallia et al. analyzed data from the National Health and Nutrition
Examination Survey from 2005 to 2010 on 2398 patients 40 or older. Patients with a
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higher exposure to cadmium were more susceptible to diabetes mellitus. Also, in
individuals that were heavy smokers were more at a higher risk for diabetes mellitus
(Wallia, Allen, Badon, & El Muayed, 2014).
In another study conducted on a Thailand population exposed to cadmium
contaminated food sources, individuals were initially tested for renal function,
hypertension, diabetes, and urinary stones with follow-up tests completed 5 years later. It
was concluded there were significant increases in tubular damage (detected by β2microglobulin urinary marker), urinary protein and serum creatinine, a decrease in
glomerular filtration rate (Swaddiwudhipong et al., 2012). There were also significant
increases in the prevalence of hypertension, diabetes mellitus, and urinary stones.
However, there was no detection in individuals who reduced their Cd2+ exposure..
There have been several studies that investigated cadmium toxicity on animal
models with or without diabetes mellitus. Many have supported the same findings as
what is observed in humans. For example, Prozialeck et al. found in rats given
subcutaneous injections of cadmium increased urinary expression of Kim-1 (marker for
proximal tubule damage), protein levels, glucose, and creatinine (Prozialeck et al., 2007).
When observing toxicant damage from a diabetes mellitus stand-point, individuals
diagnosed with type II diabetes mellitus were more prone to cadmium nephrotoxicity
than those without diabetes mellitus suggestive of cadmium accumulation contributes to
the development of diabetes mellitus (Afridi, Kazi, Brabazon, Naher, & Talpur, 2013).
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All these studies support the hypothesis of individuals exposed to low levels of
Cd2+ over a long duration of time, are more susceptible to the development of
complications associated with diabetes mellitus and ultimately the disease progression to
diabetic nephropathy. This could be due to the fact of both these toxicants target and
induce damage to the proximal tubule cells of the kidney once an accumulation threshold
is reached. When the system of the proximal tubule cell is reaching an overload of the
amount of toxicant it can protect against and another toxicant is introduced, this will
cause irreversible damage to the proximal tubule cell. It is because of this idea that at a
given point in time the general population is exposed to more than one toxicant that
researchers should investigate the damaging effects of a dual exposure on various organ
systems.
Hypothesis and Rationale
This project tests the hypothesis that cadmium has a role in the onset of the
complications associated with diabetic nephropathy through the activation of the aldose
reductase isoform, AKR1B10. In this first study, the role of cadmium or high levels
glucose exposure on the polyol pathway will be investigated in the human proximal
tubule cell model system. Preliminary results from a global gene expression analysis
revealed an induction of the aldose reductase isoform, AKR1B10, in human proximal
tubule cells exposed acutely and chronically to cadmium (Garrett et al., 2010). The first
aim of this project was to confirm AKR1B10 is induced by cadmium or hyperglycemia.
Since AKR1B10 is a newly found isoform of aldose reductase family there is little data
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on the physiological role of this enzyme so we needed to characterize the role of
AKR1B10 in human proximal tubule cells exposed to the nephrotoxicants; cadmium or
glucose. We also investigated if the other enzymes of the polyol pathway (aldose
reductase isoforms, AKR1B1 and AKR1B15 or sorbitol dehydrogenase) were induced by
cadmium or hyperglycemia in our human proximal tubule cell model.
To further characterize the role of the polyol pathway involvement in diabetic
nephropathy, sorbitol accumulation will be measured within human proximal tubule cells
exposed to cadmium or hyperglycemia. Aldose reductase metabolizes glucose to sorbitol
therefore sorbitol accumulation is an indication of aldose reductase activity. Also sorbitol
accumulation promotes osmotic stress therefore the accumulation of this osmolyte causes
the proximal tubule cell’s system to dysfunction ultimately leading to cellular death.
The second aim of this project was to investigate and characterize the effects of a
dual exposure of both cadmium and hyperglycemia on human proximal tubule cells. This
aim is designed to mimic the effect that would be seen in the general population since
there are exposures to more than one nephrotoxicant at one time. Therefore the polyol
pathway genes, as measured in the first aim, will be measured to determine if preexposure to cadmium toxicity will augment the effects seen in a hyperglycemia situation.
Although there are several studies that explored the effects of cadmium or glucose
toxicity in human diseases, no study has investigated these nephrotoxicants in an isolated
situation to look at the effects of their combined exposure on the human proximal tubule
cells.
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The final aim of this study investigated the expression of glucose transporters and
glucose utilization in the human proximal tubule cells. To ensure the current model is
best suited for investigating the effects of cadmium and hyperglycemia toxicity, we
characterized the uptake of glucose via glucose clearance from the media as well as
measured the expression of glucose transporters in these cells.
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CHAPTER I.II
METHODS
Cell Culture
There were two types of proximal tubule cells used in this study. One type was
the primary proximal tubule cells or known as human proximal tubule (HPT) cells. They
were isolated from healthy, normal sections of a human kidney. The other proximal cell
type used was an immortalized cell called human telomerase reverse transcriptase
(RPTEC/TERT1 (ATCC CRL-4031)) renal proximal tubule epithelial cells (RPTEC),
referred to as RPTEC/TERT1 (ATCC CRL-4031) cells. These epithelial cells were
immortalized with the human telomerase reverse transcriptase gene using the pLXSN
vector, allowing these cells to have an infinite life-span.
HPT were grown using serum-free conditions and collagen coated culture flasks
as described previously (Detrisac et al., 1984; Kim et al., 2002). Stock cultures were fed
growth media comprised of a 1:1 mixtures of Dulbecco’s modified eagle’s medium
(DME) and Ham’s F-12 growth medium supplemented with selenium (5 ng/ml), insulin
(5 µg/ml), transferrin (5 µg/ml), hydrocortisone (36 ng/ml), triiodothyronine (4 pg/ml)
and epidermal growth factor (10 ng/ml). The cells were fed fresh-growth medium every 2
days and were subcultured 1:2 at confluency (~8 days post subculture) using trypsinEDTA (.05% - .02%). RPTEC/TERT1 (ATCC CRL-4031) cells were obtained from the
American Type Culture Collection, expanded according to recommended culture
conditions, and aliquots were stored in liquid nitrogen.
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For the glucose studies, glucose was added to growth media that contained
a 1:1 mixture of a glucose free DME and Ham’s-F12 such that the final glucose
concentrations in the media were: 5.5, 7.5, 11, 16, 27.5, 36, 100 mM. Unless otherwise
mentioned the culture media had the same concentration of all aforementioned growth
factors.
RNA isolation and RT-qPCR
Total RNA was purified from cultures of HPT or RPTEC/TERT1 (ATCC CRL4031) cells utilizing TRI Reagent (Molecular Research Center, Inc.) and quantified by
spectrophotometry (Nanodrop). 100 ng of total RNA was subjected to cDNA synthesis
using the iScript cDNA synthesis kit (Bio-Rad) for a final volume of 20 μL. Gene
expression was measured with real-time reverse transcription polymerase chain reaction
(RT-PCR) using primers of interest (see Table 1.2.1). Real time PCR was performed
using SYBR Green (Bio-Rad) with 2 μL cDNA and .2 μM primers in a final volume of
20 μL in the CFX96 Touch Real-Time detection system (Bio-Rad). SYBR Green
fluorescence was used to monitor the amplification of the reaction and further analyzed
by interpolation from a standard curve.
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Gene
Company
AKR1B1 Qiagen
AKR1B10 Qiagen

Catalog No.
QT00088648
QT000668695

SORD
TXNIP

qHsaCED0044950
qHsaCED0043730

Biorad
Biorad

Table 1.2.1 Primer Information
Protein Isolation
For the glucose studies, total protein was isolated from HPT cells using a 2%
Sodium Dodecyl Sulfate (SDS) solution containing 50 mM Tris-HCL, pH 6.8 with 1%
protease inhibitor cocktail (Sigma-Aldrich). Cell pellets were homogenized in the lysis
buffer, boiled for 10 minutes and subjected to DNA shearing by sonication. Protein
concentration was determined by BCA assay (Pierce). Stock samples were stored at 80ºC.
For the cadmium and glucose studies with RPTEC/TERT1 (ATCC CRL-4031)
cells, total protein was isolated from the HPT and RPTEC/TERT1 (ATCC CRL-4031)
cells using a RIPA lysis buffer containing protease inhibitors, PMSF, and sodium
orthovandate (Santa Cruz). Cell pellets were homogenized in cold RIPA lysis buffer at a
1:2 w/v ratio and incubated on ice, with orbital shaking for 30 minutes. The samples were
then sonicated and centrifuged at 10,000g for 10 minutes at 4°C. The supernatant was
collected in cold, separate tubes and subjected to BCA assay (Pierce) for protein
quantification and stored -80ºC.
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Western Blot Analysis
Protein expression was measured by Western blot techniques. Twenty µg protein
was separated by SDS-Page using the TGX AnyKd SDS polyacrylamide gel (Bio-Rad).
Samples contained equal amounts of protein and Laemmli buffer (Bio-Rad) containing βmercaptoethanol. The samples were then boiled for 5 minutes at 95ºC to reduce protein.
Once samples were back to room temperature, they were loaded into the gel. Proteins
were then transferred to a .2 µm PVDF membrane using a Trans-blot Turbo transfer
apparatus (Bio-Rad). After transfer, the membranes were blocked with 5% nonfat dry
milk in TBS-T for 90 minutes. Blots were incubated in 4ºC in the primary antibodies
overnight on an orbital shaker. Table 1.2.1 has a list of all antibodies.
Antibody Name

Mw (kDa)

Dilution

Species

Company

Catalog No.

AKR1B10

36

1:1000

Rabbit

Abcam

Ab192865

AKR1B1

36

1:1000

Rabbit

Abcam

Ab62795

BETA ACTIN

42

1:3000

Mouse

Abcam

Ab8226

TXNIP

44

1:1000

Rabbit

Abcam

Ab188865

Table 1.2.2 Antibody source.
Glucose Utilization
Glucose utilization by HPT and RPTEC/TERT1 (ATCC CRL-4031) cells
exposed to 5.5, 7.75, 11, 16mM glucose was measured. Glucose utilization was measured
using a glucose colorimetric assay kit II (Biovision). Briefly, media was collected 48
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hours post-feed from HPT cells fed 5.5, 7.75, 11, 16 mM of glucose and frozen in -20°C.
The media was thawed at room temperature where 300 μL of the collected media was
centrifuged in a 10 kDa spin cut-off filter (Millipore). The flow through was collected
and used to measure glucose utilization. A standard curve was prepared using a 1
nmol/μL glucose standard to generate 0, 2, 4, 6, 8, and 10 nmol/well; bringing the final
volume to 50 μL using the supplied assay buffer. A 50 μL/well glucose reaction mix was
prepared with the following components: 46 μL Glucose Assay Buffer, 2 μL Glucose
Enzyme, 2 μL Glucose substrate, according to supplier’s protocol. Reagents and samples
were added to a 96 well plate and incubated for 30 minutes at 37°C, protected from light.
The absorbance was measured at 450 nm on Biotek FLx800 plate reader.
Sorbitol Assay
Sorbitol accumulation in the HPT and RPTEC/TERT1 (ATCC CRL-4031) cells
was measured using a D-sorbitol colorimetric assay kit (Biovision). Briefly, HPT cells
exposed to 5.5, 7.75, 11, 16 mM glucose concentrations were harvested in nuclease-free
water and stored at -80°C until used. HPT cells were thawed at room temperature,
subjected to brief sonication, and centrifuged at 4°C at 13,200 rpm for 10 minutes.
Supernatant was used for sorbitol accumulation measurements. A standard curve was
prepared using a 1 nmol/μL sorbitol standard to generate 0, 2, 4, 6, 8, and 10 nmol/well;
bringing the final volume to 50 μL using the supplied assay buffer. A 50 μL/well glucose
reaction mix was prepared with the following components: 36 μL sorbitol assay buffer, 2
μL sorbitol Enzyme, 2 μL sorbitol probe, 10 μL sorbitol developer, according to
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supplier’s protocol. Reagents and samples were added to a 96 well plate and incubated
for 30 minutes at 37°C, protected from light. The absorbance was measured at 570 nm on
Biotek FLx800 plate reader.
Cell Proliferation Assay
Cell viability and proliferation was measured in HPT and RPTEC/TERT1 (ATCC
CRL-4031) cells exposed to 5.5, 7.75, 11, 16 mM glucose using 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich, MO). For cell
proliferation, confluent cultures were split at a seeding density of ~20,000 cells per well
into 6 well plates. Starting on day 2 post-seed, cells were treated with the different
glucose concentrations. Day 3 post-seed, 40 μL of MTT reagent (5 mg/ml) was added to
each well. One well containing no cells but media with MTT reagent was included in the
analysis for the control. Plates were incubated for 3.5 hours at 37°C, followed by multiple
(3x) PBS washes. 1 ml of acidic propanol was added to each well and placed on orbital
shaker for 5 minutes, covered in tinfoil. Each well was mixed well then 200 μL of sample
was added to a 96 well assay plate (flat bottom), done in triplicate. The optical density
was immediately measured at 570 nm on a BioTek FLx800 plate reader (BioTek
Instruments INC, Winooski, VT). The final optical density readings were subtracted from
blank and used to calculate cell proliferation. Values were read every day for 12 days.
For cell viability measurements, confluent cultures were split at a seeding density
of 300,000 cells per well into 6 well plates. Once confluent and doming, cells were then
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exposed to the various concentrations of glucose. Day 2 post-treatment (24 hour glucose
exposure), completed the MTT cell viability assay similar to the protocol for cell
proliferation.
Transient Knockdown of AKR1B10
AKR1B10 expression was silenced in HPT and RPTEC/TERT1 (ATCC CRL4031) using a siRNA (Qiagen) and lipofectamine methods. Cells were seeded at
~800,000 cells per well in a 6-well plate. 24 hours post-seed, a solution containing a
siRNA for AKR1B10 and TransIT-X2 transfection reagent in serum- free medium was
added to each well for final concentration of 20 µM and 50 nM, respectively
(siRNA:TransIT complexes formed). 250 µL siRNA and transfection solution was added
to each well in a drop-wise fashion. The plate was gently rocked back-and-forth and from
side-to-side to evenly distribute the siRNA:TransIT complexes. The plates were
incubated for 48 hours prior to treating with 5.5, 7.5, 11, or 16 mM glucose
concentrations for 24 hours.
Statistical Analysis
All experiments were performed either in triplicate or duplicate and the results
were expressed as the standard error of the mean. Data sets were subjected to statistical
analyses using GraphPad Prism® software. Statistical analyses performed was separate
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variance t-tests, ANOVA with Tukey or Dunnett’s post-hoc testing. The level of
significance was *p<.05, **p<.01, ***p<.001.
Microarray Analysis
Gene expression analysis was performed by Biomedical Genomics Center at the
University of Minnesota (Minneapolis, MN). Isolation of total RNA was completed using
a Qiagen RNeasy Mini Kit (Qiagen, CA) according to manufacturer’s instructions. A
total of 100 ng of RNA was used for Genome wide expression which was determined
using a Human HT-12v4 Expression BeadChip array (Illumina, CA) (discontinued in
2016). Briefly, RNA was amplified and biotin-labeled using a labeling kit recommended
by Illumina. The labeled RNA (cRNA) was quantitated using a Quant-iT RiboGreen
RNA assay kit. cRNA was normalized and hybridized to the Illumina HT-12v4.0
BeadChips. Probes are then detected using Cy3-Streptavidin for differential detection of
signals. Images from the BeadChips are then analyzed using Illumina’s GenomeStudio
Gene Expression Module. The data output was analyzed for differentially expressed
genes by the Bioinformatics core facility at the University of North Dakota School of
Medicine and Health Science. Differentially expressed probe sets (DEGs) were identified
using empirical Bayes method and p-values adjusted using false discovery rate. R
programming language and SAS JMPH software was used to analyze data.
CHAPTER I.III
RESULTS
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Expression of AKR1B1, AKR1B10, SORD in Cd2+ Exposed HPT and
RPTEC/TERT1 (ATCC CRL-4031) cells
Results from a global gene microarray expression analysis completed on HPT
cells exposed to various concentrations of Cd2+ for 24 hours (acute) or 13 days (chronic)
showed an induction AKR1B10. RPTEC/TERT1 (ATCC CRL-4031) were also exposed
to various concentrations of Cd2+ for 24 hours (acute) or 13 days (chronic) and were
analyzed for AKR1B1, AKR1B10, SORD expression. The results from both the HPT and
RPTEC/TERT1 (ATCC CRL-4031) were compared to each other to determine if Cd2+
exposures have the same effect on the polyol pathway in immortalized proximal tubule
cells as primary proximal tubule cells.
The expression of aldose reductase genes, AKR1B1 and AKR1B10 was measured
to confirm the results of the global gene microarray of Cd2+ exposed HPT cells. Realtime PCR was performed in the human proximal tubule cells exposed acutely or
chronically to Cd2+. Both AKR1B1 and AKR1B10 expression was found to be
significantly induced in HPT cells exposed to 27 and 45 µM Cd2+ for 24 hours (acute)
(Figure 1.3.1. A, B). Acute Cd2+ exposures had no effect on SORD expression (Figure
1.3.2. C). Western blot analysis showed AKR1B10 protein levels were also induced by
Cd2+ exposures whereas AKR1B1 were not (Figure 1.3.1. C, D ).
Similarly, AKR1B1 and AKR1B10 expression was found to be significantly
induced in HPT cells exposed to 9 and 27 µM Cd2+ for 13 days (chronic) (Figure 1.3.2.
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A, B). Chronic Cd2+ exposures had no effect on SORD expression (Figure 1.3.2. C).
Western blot analysis showed AKR1B10 protein levels were also induced by Cd2+
exposures whereas AKR1B1 were not (Figure 1.3.2. C, D).
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Figure 1.3.1 AKR1B1 and AKR1B10 expression is induced by acute exposures to
Cd2+ in HPT cells. RT-PCR analysis of AKR1B1 (A), AKR1B10 (B), and SORD (E) in
HPT cells exposed to Cd2+ for 24 hours expressed as a fold change normalized to βactin. Western blot analysis of AKR1B1 (C) and AKR1B10 (D) proteins in HPT cells
exposed to Cd2+ for 24 hours. RT-PCR results represent ±SEM of triplicate. *p<0.05,
**p<0.01, ***p<0.001
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Figure 1.3.2 AKR1B1 and AKR1B10 mRNA expression is induced by chronic
exposures to Cd2+ in HPT cells. RT-PCR analysis of AKR1B1 (A), AKR1B10 (B), and
SORD (E) in HPT cells exposed to Cd2+ for 13 days expressed as a fold change
normalized to β- actin. Western blot analysis of AKR1B1 (C), AKR1B10 (D) proteins in
HPT cells exposed to Cd2+ for 13 days. RT-PCR results represent ±SEM of triplicate.
*p<0.05, **p<0.01, ***p<0.001.
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As a means to compare and determine Cd2+ toxicity between a primary and an
immortalized proximal tubule cell model, the expression of AKR1B1, AKR1B10, and
SORD was measured in the RPTEC/TERT1 (ATCC CRL-4031) cells exposed acutely or
chronically to Cd2+.
Similar to the HPT cells, RPTEC/TERT1 (ATCC CRL-4031) cells showed
appreciable inductions of the AKR1B10 but not AKR1B1 and SORD by Cd2+ toxicity
(Figure 1.3.3). Cd2+ concentrations had to be adjusted because RPTEC/TERT1 (ATCC
CRL-4031) cells were more sensitive to Cd2+ toxicity induced cell death.AKR1B1 and
SORD expression was also unaffected by chronic exposures to Cd2+ toxicity but
AKR1B10 is significantly induced at the mRNA levels (Figure 1.3.4 B) and there is also
an increase in protein expression (Figure 1.3.4 D).
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Figure 1.3.3 AKR1B1 and AKR1B10 expression is induced by acute exposures to
Cd2+ in RPTEC/TERT1 (ATCC CRL-4031) cells. RT-PCR analysis of AKR1B1 (A),
AKR1B10 (B), and SORD (C) in RPTEC/TERT1 (ATCC CRL-4031) cells exposed to
Cd2+ for 24 hours expressed as a fold change normalized to β- actin. Western blot
analysis of AKR1B1 (C) and AKR1B10 (D) in RPTEC/TERT1 (ATCC CRL-4031) cells
exposed to Cd2+ for 24 hours. RT-PCR results represent ±SEM of triplicate. *p<0.05,
**p<0.01, ***p<0.001.
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Figure 1.3.4 AKR1B1 and AKR1B10 expression is induced by chronic exposures to
Cd2+ in RPTEC/TERT1 (ATCC CRL-4031) cells. RT-PCR analysis of AKR1B1 (A),
AKR1B10 (B), and SORD (E) in RPTEC/TERT1 (ATCC CRL-4031) cells exposed to
Cd2+ for 13 days expressed as a fold change normalized to β- actin. Western blot analysis
of AKR1B1 (C) and AKR1B10 (D) proteins in RPTEC/TERT1 (ATCC CRL-4031) cells
exposed to Cd2+ for 13 days. RT-PCR results represent ±SEM of triplicate. *p<0.05,
**p<0.01, ***p<0.001.
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Since the expression of the aldose reductase enzymes was induced by Cd2+, it was
determined if other metals studied by this lab had an effect on these enzymes as well.
Measured the expression levels of AKR1B1, AKR1B10, and SORD in HPT cells acutely
exposed to 100 µM As3+. Starting at 8 hours post-exposure (recovery) to 100 µM As3+,
there is a 2.5 fold induction of AKR1B1 and AKR1B10 with no significant induction of
SORD (Figure 1.3.6 A, B, C, respectively). The induction of AKR1B1 slowly regressed
back to control levels by 48 hours post-exposure. On the other hand, AKR1B10 reached
maximum induction (3.5 fold induction) by 12 hours post-exposure.

Figure 1.3.5 AKR1B10 and AKR1B10 expression is induced by acute exposures to
As3+ in HPT cells. RT-PCR analysis of AKR1B1 (A) and AKR1B10 (B) in HPT cells
exposed to As3+ for 4 hours expressed as a fold change normalized to β- actin. RT-PCR
results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001.
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Preliminary Glucose Studies on Primary Human Proximal Tubule Cells
Since most studies investigating diabetes mellitus use non-physiological relevant
concentrations of glucose in relation to the disease, a range of glucose concentrations was
used from 5.5 to 100 mM. It was determined what glucose concentrations primary or
immortalized proximal tubule cells can tolerate.
Initially, when trying to determine which glucose concentrations to use to study
the effects of hyperglycemia on primary HPT cells a range from 7.5 to 40 mM glucose
was used. Primary HPT cells exposed to the 7.5, 15, 22.5, 37.5 mM glucose for 7 days.
There was no noticeable cell death when cell morphology was observed under a phasecontrast microscope. AKR1B1 expression was induced 1.4, 1.3, 2.4 fold by 15, 22.5, 37.5
mM glucose, respectively whereas AKR1B10 4.5, 2.5, 2 fold induction by 15, 22.5, 37.5
mM glucose, respectively (Figure 1.3.6 A, B). Since this was a pilot study to test the
tolerance concentrations of glucose in primary HPT cells, protein analysis was not
conducted.
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Figure 1.3.6 Preliminary results of AKR1B1 and AKR1B10 expression in HPT cells
exposed to various concentrations of glucose. RT-PCR analysis of AKR1B1 (A), and
AKR1B10 (B) in HPT cells exposed to 7.5, 15, 22.5, 37.5 mM glucose expressed as a
fold change normalized to control. RT-PCR results represent ±SEM of triplicate.
*p<0.05, **p<0.01, ***p<0.001

In another pilot study, it was determined if the feeding schedule needed to be
adjusted for the optimal results. The feeding schedule of treatments is an important player
in the resulting effects. Typically, cultured cells are fed every other day. It was tested
how the primary or immortalized HPT cells handled a longer feeding schedule; fed every
3 days, with higher dosages of glucose.
Primary HPT cells were exposed and continuously passaged in higher glucose
concentrations for 24 days. Also, the feeding schedule was changed from 2 days to 3.
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Although the cells were able to handle the increased glucose concentrations, there was an
increased production of lactate as seen in the color change of the media.

Figure 1.3.8 Preliminary results of AKR1B1 and AKR1B10 expression in
RPTEC/TERT1 (ATCC CRL-4031) cells exposed to various concentrations of
glucose every 3 days. RT-PCR analysis of AKR1B1 (A) and AKR1B10 (B) in
RPTEC/TERT1 (ATCC CRL-4031) cells exposed to 5.5, 16, 27.5, 100 mM glucose
expressed as a fold change normalized to control. RT-PCR results represent ±SEM of
triplicate. *p<0.05, **p<0.01, ***p<0.001

Expression of AKR1B1, AKR1B10, SORD in High Glucose Exposed HPT and
RPTEC/TERT1 (ATCC CRL-4031) cells
AKR1B10 is an isoform of the aldose reductase, AKR1B1, however the effects of
hyperglycemia on this alternative isoform are not known. In order to determine if
hyperglycemia induced the expression of AKR1B1, AKR1B10, and SORD in HPT and

42

RPTEC/TERT1 (ATCC CRL-4031) cells, confluent HPT or RPTEC/TERT1 (ATCC
CRL-4031) cells were exposed to 5.5, 7.5 or 7.75, 11, or 16 mM glucose concentrations
for 8 days then passaged and continuously exposed to various concentrations of glucose
for another 8 days (P2). This process was repeated twice, with the cells in the final
passage labeled as P3 and having a total glucose exposure of 24 days.
AKR1B1 expression is not induced by increasing glucose concentrations in
primary HPT cells (Figure 1.3.9 A).
AKR1B10 expression had a 2 fold induction in 7.5 and 11 mM and a 3.5 fold
inductions in HPT cells exposed to glucose for 8 days (P1). AKR1B10 expression was
maximally induced in HPT cells by 11 and 16 mM glucose in a 16 day exposure (P2) and
after 24 days (P3) of glucose exposure, AKR1B10 expression was only induced 2.7 fold
by 16 mM glucose (Figure 1.3.9 B).
Glucose exposure had a minimal effect on SORD expression. In an 8 day (P1)
exposure, 7.5, 11, 16 mM glucose induced SORD by 1.5 fold. There was no induction of
SORD expression in 16 (P2) or 24 (P3) day glucose exposure (Figure 1.3.9 E).
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Figure 1.3.9 AKR1B1 and AKR1B10 expression is induced in HPT cells exposed
and passaged in glucose. RT-PCR analysis of AKR1B1 (A), AKR1B10 (B), and SORD
(C) in HPT cells exposed to 5.5, 7.5, 11, 16 mM glucose expressed as a fold change
normalized to β- actin. Western blot analysis of AKR1B1 (D) and AKR1B10 (E) proteins
in HPT cells exposed to glucose. RT-PCR results represent ±SEM of triplicate. *p<0.05,
**p<0.01, ***p<0.001.
44

The activation of the polyol pathway in response to glucose toxicity was
measured and compared to the RPTEC/TERT1 (ATCC CRL-4031) cells exposed and
passaged in the same concentrations of glucose as HPT cells; 5.5, 7.5, 11, 16 mM.
AKR1B1, AKR1B10, SORD expression was not induced by glucose in
RPTEC/TERT1 (ATCC CRL-4031) cells (Figure 1.3.10 A, B, C).
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Figure 1.3.10 AKR1B1, AKR1B10, SORD expression is not induced in
RPTEC/TERT1 (ATCC CRL-4031) cells exposed and passaged in glucose. RT-PCR
analysis of AKR1B1 (A), AKR1B10 (B), and SORD (C) in RPTEC/TERT1 (ATCC
CRL-4031) cells exposed to 5.5, 7.5, 11, 16 mM glucose expressed as a fold change
normalized to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01,
***p<0.001
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Glucose utilization in HPT and RPTEC/TERT1 (ATCC CRL-4031) cells exposed to
glucose
Glucose utilization was measured in HPT and RPTEC/TERT1 (ATCC CRL4031) cells exposed to glucose for 48 hours. This measurement correlated with the
glucose clearance by these cells since they were fed every other day.
Media was collected on every feed day from HPT cells exposed to 5.5, 7.5, 11, 16
mM glucose for 8 days. Figure 1.3.11 represents two different measurements of glucose
utilization by the HPT cells. D2 and D7 stands for day 2 and 7 of feeding, respectively.
48 hours post feed, media was collected from the flask with HPT cells and subjected to
glucose analysis by the glucose assay. These measurements are critical not only to ensure
the HPT cells are metabolizing and transporting the glucose but also to estimate the
amount of glucose being metabolized.
In both D2 and D7, HPT cells metabolized all of the glucose in 5.5 and 7.75 mM,
97% of the glucose in 11 mM, 87% of the glucose in 16 mM media (Figure 1.3.11). Since
the earliest measurement of glucose utilization was 48 hours post-feed, a similar
experiment was conducted. HPT cells were exposed to 5.5, 7.75, 11, 16, 27.5, 100 mM
glucose for 24 or 48 hours and glucose utilization was measured. At both time points,
nearly all the glucose had been metabolized (Figure 1.3.12 A and B).
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Figure 1.3.11 Glucose utilization by HPT cells exposed to glucose for 8 days.
Glucose utilization in HPT cells exposed to 5.5, 7.5, 11, or 16 mM glucose for 8 days
expressed as mM. Results represent ±SEM of triplicate.
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Figure 1.3.12 Glucose utilization by HPT cells exposed to glucose for 24 or 48 hours.
Glucose utilization by HPT cells exposed to 5.5, 7.5, 11, 16, 27.5, 100 mM glucose for 24
(A) or 48 (B) hours expressed as mM. Results represent ±SEM of triplicate.

Intracellular sorbitol accumulation in HPT and RPTEC/TERT1 (ATCC CRL-4031)
cells exposed to glucose
In a state of hyperglycemia, activation of the aldose reductase enzymes of the
polyol pathway leads to the production of increased intracellular sorbitol accumulation.
mRNA and protein levels showed an increased expression levels of AKR1B1 and
AKR1B10, intracellular sorbitol measurements were made as a means to determine
enzyme activity.
Intracellular sorbitol measurements were made in primary HPT cells exposed to
5.5, 7.75, 11, 16, 27.5, 100 mM glucose for 8 days and fed every other day. There is a 349

fold induction of intracellular sorbitol accumulation when HPT cells are exposed to 7.75
mM glucose for 8 days as compared to the control (5.5 mM) and a 10 to 25-fold
induction as the glucose concentration is increased.
Sorbitol accumulation can be seen as early as 24 hours in HPT cells exposed to
various concentrations of glucose. At a 24-hour exposure, HPT have a significant
accumulation of sorbitol from 11 to 100 mM glucose (Figure 1.3.12 A). Similarly, at 48hour glucose exposure, there is a significant accumulation of sorbitol starting at 11 mM
glucose (Figure 1.3.12 B)
When measurements for sorbitol accumulation were taken in RPTEC/TERT1
(ATCC CRL-4031) cells exposed to the same conditions as the HPT cells, there were no
sorbitol accumulation (data not shown).
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Figure 1.3.13 Intracellular sorbitol accumulation is increased in HPT cells with
increased glucose concentration in an 8-day exposure. Intracellular sorbitol
measurements in HPT cells exposed to 5.5, 7.5, 11, 16, 27.5, 100 mM glucose for 8 days
expressed as nmol/10^6 cells. Results represent ±SEM of triplicate. *p<0.05, **p<0.01,
***p<0.001
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Figure 1.3.14 Intracellular sorbitol accumulation is increased in HPT cells with
increased glucose concentration in 24 or 48-hour exposure. Intracellular sorbitol
measurements in HPT cells exposed to 5.5, 7.5, 11, 16, 27.5, 100 mM glucose for 24 (A)
or 48 (B) hours expressed as nmol/10^6 cells. Results represent ±SEM of triplicate.
*p<0.05, **p<0.01, ***p<0.001

Knock-down of AKR1B10 Attenuates Sorbitol Accumulation in HPT Cells Exposed
to Glucose
Since AKR1B10 was more sensitive to glucose toxicity, it was determined if a
transient knock-down of AKR1B10 would attenuate sorbitol accumulation seen in HPT
cells exposed to glucose. Previous publications from this lab has showed knock-down of
AKR1B1 by an inhibitor also showed a reduction of sorbitol accumulation but since little
was known of AKR1B10 isoform and glucose toxicity, it needed to be investigated.
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In HPT cells that were transiently transfected with a siRNA targeted for
AKR1B10 and exposed to 5.5, 7.75, 11, 16 mM glucose for 24 hours showed a
significant reduction in sorbitol accumulation (Figure 1.3.15 B).

Figure 1.3.15 Intracellular sorbitol accumulation is decreased in HPT cells with
AKR1B10 knock-down. RT-PCR analysis of AKR1B10 in AKR1B10 knock-down HPT
cells (A) exposed to 5.5, 7.5, 11, 16 mM glucose for 24 hours expressed as a fold change
normalized to ACTB. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01,
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***p<0.001. Intracellular sorbitol measurements in AKR1B10 knock down HPT cells
(B) exposed to 5.5, 7.5, 11, 16 mM glucose for 24 hours expressed as nmol/10^6 cells.
Results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001

Exposures to Hyperglycemic Conditions had no Effect on HPT Cell Proliferation or
Viability
Hyperglycemia conditions had no effect on both the cell viability and
proliferation. For cell proliferation, cells were seeded at a small percentage (1:100) such
that they wouldn’t reach a growth plateau until 8 days or later. The growing cells exposed
to 5.5, 7.5, 11, 16 mM glucose had no decrease in cell growth (Figure 1.3.16). For cell
viability, confluent cultures (~8 days post-seed) were treated with the same
concentrations of glucose previously mentioned. There was no cell death in response to
the hyperglycemic conditions (Figure 1.3.17).
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Figure 1.3.16 Cell proliferation in HPT cells exposed to hyperglycemia. Cell
proliferation curves for HPT cells exposed to 5.5, 7.5, 11, 16 mM glucose for 6 days
(measurements were taken starting day 4 post-seed). The glucose treatments had no
effect on HPT cell proliferation.
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Figure 1.3.17 Cell viability in HPT cells exposed to hyperglycemia. HPT cells
exposed to 5.5, 7.5, 11, or 16 mM glucose over a 8 day period had no changes in cell
viability.

Glucose Transporters absent in primary and immortalized kidney cell model
systems
There have been reports of increased glucose transporter expression when
exposed to high glucose concentrations therefore the expression levels of the sodium
coupled glucose and facilitated glucose transporters based on the effects of glucose
exposures in HPT and RPTEC/TERT1 (ATCC CRL-4031) cells was measured
(Rahmoune et al., 2005; Umino et al., 2018).
In both HPT and RPTEC/TERT1 (ATCC CRL-4031) cells exposed and passaged
in 5.5, 7.5/7.75, 11, and 16 mM glucose showed very little to no expression of SGLT1
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(Figure 1.3.18 A), SGLT2 (Figure 1.3.18 B), and GLUT2. Other kidney cell models;
RPTEC/TERT1 (ATCC CRL-4031), HK2, HK2-MT3, HPT-3, HPT-4, HPT-5, and
whole kidney systems were tested for the expression of these transporters. Whole kidney
sample had the highest expression of all SLC5A1 and SLC5A2 transporters (Figure
1.3.18 A, B).

Figure 1.3.18 SLC5A1 and SLC5A2 expression in various kidney samples. RT-PCR
analysis of SLC5A1 (A) and SLC5A2 (B) in various kidney samples grown in 2012 or
HPT-4 cells exposed to 5.5, 7.75, 11, 16 mM glucose for 8 days. Data expressed as fold
change normalized to whole kidney
The expression of GLUT2 in the same set of kidney samples as in Figure 1.3.18 is
not shown because the expression was so low or not detected in some of the samples.
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HPT Cells do not Elicit an Additive Response to the Combine Glucose and Cd2+
Exposure
Using in vitro model systems to study diseases helps to understand an isolated
response that may occur due to exposures to a single toxicant or drug. Since the general
population is exposed to more than one toxicant at time and there has been more support
of cadmium toxicity having a role in diabetic nephropathy, the effects of a combined
glucose and cadmium exposure was determined on HPT cells. RPTEC/TERT1 (ATCC
CRL-4031) cells were not used for this part of the study since they didn’t respond to the
glucose toxicity.
HPT cells were exposed to low levels of Cd2+ (4.5 or 9 µM) for 72 hours then 5.5,
7.75, 11, or 16 mM glucose was added for a combined exposure of 48 hours. There are
significant inductions of both AKR1B1 and AKR1B10 in HPT cells exposed separately
to glucose or Cd2+only. Also both AKR1B1 and AKR1B10 are induced by the combined
exposure of Cd2+ and glucose however the response in not additive to what is seen by
separate toxicant exposure (Figure 1.3.19 A and B).
Intracellular sorbitol accumulation was also measured in HPT cells exposed to
both cadmium and hyperglycemia. Although there is a significant induction of sorbitol
accumulation in HPT exposed to hyperglycemic conditions for 48 hours, there is not an
increased accumulation of sorbitol when exposed to both cadmium and hyperglycemic
conditions (Figure 1.3.20).
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Figure 1.3.19 AKR1B1 and AKR1B10 expression is induced by combined exposures
to Cd2+ and Glucose in HPT cells. RT-PCR analysis of AKR1B1 (A) and AKR1B10
(B) in HPT cells exposed to 4.5 or 9 µM Cd2+ for 72 hours then added 5.5, 7.5, 11, 16
mM glucose for a combined exposure for 48 hours. Data expressed as a fold change
normalized to control. Western blot analysis of AKR1B1 (D) and AKR1B10 (E) proteins
in HPT cells exposed to 4.5 or 9 µM Cd2+ for 72 hours then added 5.5, 7.5, 11, 16 mM
glucose for a combined exposure for 48 hours. RT-PCR results represent ±SEM of
triplicate. *p<0.05, **p<0.01, ***p<0.001
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Figure 1.3.20 Intracellular sorbitol accumulation is increased in HPT cells in a
combined exposure to Cd2+ and Glucose. Intracellular sorbitol measurements in HPT
cells HPT cells exposed to 4.5 or 9 µM Cd2+ for 72 hours then added 5.5, 7.5, 11, 16 mM
glucose for a combined exposure for 48 hours. Data expressed as nmol/10^6 cells.
Results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001

Global Gene Analysis on Primary Human Proximal Tubule Cells Exposed to High
Glucose concentrations for 24 days (P3)
The disease etiology of diabetic nephropathy is highly complicated and not
subjected to a single cause. There are numerous contributors to the onset and progression
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of the disease. With this in mind, to investigate what other pathways or genes that may be
activated in response to glucose toxicity in HPT cells, HPT cells that were passaged and
exposed to glucose for 24 days (P3) was subjected to global gene analysis.
Results from the global microarray had shown little gene induction although,
there was one gene significantly induced in the 16 mM glucose compared to 5.5 mM
(control). This gene was thioredoxin-interacting protein (TXNIP). TXNIP is an oxidative
stress marker that binds and inhibits thioredoxin protein promoting oxidative stress.
To confirm the microarray data, TXNIP expression was measured in HPT cells
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. In the first passage, there is a 50fold induction of TXNIP expression at the mRNA level in HPT cells exposed to 16 mM
glucose for 8 days. In the later passages, TXNIP is still significantly induced by the
glucose exposures just not as significant as the first passage (Figure 1.3.21).
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Figure 1.3.21 TXNIP expression is induced in HPT cells exposed and passaged in
glucose. RT-PCRand protein analysis of TXNIP in HPT cells exposed and passaged in
5.5, 7.5, 11, 06 16 mM glucose. Data expressed as a fold change normalized to ACTB.
RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001
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CHAPTER I.IV
DISCUSSION
Establishing a Proper Model for Investigating Diabetic Nephropathy
Diabetic nephropathy is a major complication in individuals stricken with diabetes
mellitus. Although there have been several pathophysiological insights there still remains
a successful treatment for inhibiting the disease progression to the onset of more severe
complications such as fibrosis. This is partly due to complicated nature of the disease
with several contributing factors that have a role in the disease etiology. The main new
findings of this study that will contribute to the diabetic nephropathy field are the roles of
AKR1B10 in glucose toxicity but the role of cadmium induced toxicity in contributing to
the disease onset. With the exception of one publication from Shaw et al.2014 AKR1B10
hasn’t been studied in the context of diabetes nephropathy or cadmium induced diseases
therefore this study will help in the development of new treatments to target AKR1B10
for both diseases. This study is also the first to investigate the effects the combined
effects of cadmium and glucose toxicity and the usage of a human primary cell model
system to characterize complications of diabetic nephropathy.
Most studies investigating or characterizing the pathophysiology of cell model
systems in hyperglycemic conditions as a means to better understand complications
associated with diabetes mellitus have used non-physiological relevant concentrations of
glucose. Therefore to properly investigate the glucose handling by proximal tubule cells
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of the kidney and how hyperglycemia induces damage, we had to test multiple glucose
concentrations and conditions for this study.
Since diabetic nephropathy is a progressive disease, kidney cells are
continuously exposed to hyperglycemic conditions for long periods of time. Therefore the
duration of the hyperglycemic exposure was also addressed and manipulated such that it
would properly elicit a response seen in diabetic nephropathy. With these conditions in
mind, the first goal was to determine how well the HPT cells responded to a longer
exposure period and also if they could tolerate being passaged in hyperglycemic
conditions.
Both HPT and RPTEC/TERT1 (ATCC CRL-4031) cells were able to tolerate
exposures to and passage in the hyperglycemic conditions with no cell death evident of
the cell viability assay. However, prolonged exposures to the hyperglycemic conditions
underwent a morphology change. These cells were more elongated and less cuboidal in
shape as seen in the earlier passages. When processes like this occur, it’s commonly
associated with an epithelial to mesenchymal transition that is known to have a role in the
onset of fibrosis that occurs in the severe disease states of diabetic nephropathy (Carew,
Wang, & Kantharidis, 2012b; Grabias & Konstantopoulos, 2014). This phenomenon is
addressed in more detail in the second chapter.
Although the cell model systems utilized in this study were able to tolerate the
hyperglycemic conditions, they are missing or have low expression of key glucose
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transporters. The proximal tubule cell is well- known of its reabsorbing and transporting
properties however through the culturing process of these cells they lose their brush
border. Sodium-coupled transporters which is the primary source of glucose re-uptake by
these cells is located in the brush border which could explain the lack of expression in the
proximal tubule cell model systems. However the lack of these transporters in proximal
tubule cell model systems is not addressed in literature.
Since all proximal tubule cell model systems utilized by this lab lack these
transporters, to get a better understanding of complications induced by hyperglycemic
exposures, the primary HPT cells would be better model system to use. The HPT cells
were more sensitive to the different glucose concentrations in comparison to the lack of
response by the immortalized RPTEC/TERT1 (ATCC CRL-4031) cell model system.
Also when investigating human diseases, it is ideal to use human model systems because
they will elicit the closest pathophysiological response as the seen in the organ.
To have the best model to use for studying diabetic nephropathy, it would need all
its physiological properties. As a future direction for this study, the HPT cells should be
transfected with a sodium- coupled transporter and this study re-investigated.
Involvement of AKR1B10 in Hyperglycemic Conditions
As mentioned in the introduction, the polyol pathway has been heavily studied
since its first discoveries and role in diabetic cataracts (Das & Srivastava, 1985; Shaw et
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al., 2014; VAN HEYNINGEN, 1959). Findings from these earlier studies eluded to
sorbitol accumulation being the driving factor for complications associated with diabetes
cataracts and inhibition of aldose reductase eliminates such complications. These findings
set the stage for future investigations of complications of diabetic mellitus.
Previous studies from this lab have investigated the response of HPT cells
exposed to hyperglycemic conditions through the polyol pathway. Initial studies have
shown HPT cells exposed to glucose concentration ≥11 mM for 24 hours have a 2-fold
induction of aldose reductase, AKR1B1, activity and induction of sorbitol accumulation
that is reduced to normal levels when AKR1B1 is inhibited (Bylander & Sens, 1990)The
early studies and evidence for the involvement of the polyol pathway in diabetes mellitus
complications became the new target for the establishment of pharmaceutical inhibitors
and treatments for this disease (Dvornik et al., 1973; Hotta et al., 2006; Srivastava,
Ramana, & Bhatnagar, 2005). The fact that AKR1B1 expression in HPT cells is induced
within the first 8 days of exposure to hyperglycemic conditions but not the latter passages
is highly suggestive of the initial involvement of this isoform in contributing to sorbitol
accumulation. Whereas long-term damage that is associated prolong exposures to
hyperglycemic conditions is contributed to by this other aldose reductase isoform,
AKR1B10.
AKR1B1 and AKR1B10 belong to same aldose reductase family of the polyol
pathway (Petrash, Flath, Sens, & Bylander, 1992). These enzymes are responsible for
66

metabolizing intracellular toxic carbonyl compounds in physiological conditions however
in a state of hyperglycemia metabolizes the extra glucose to sorbitol rendering the system
highly susceptible to damage by reactive oxygen species (Michael Brownlee, 2005;
Crosas et al., 2003; Huang et al., 2016).
The results from these studies have demonstrated that prolong exposures to
hyperglycemia induce the expression of AKR1B10 and knock down of this isoform
significantly decreases the amount of intracellular accumulated sorbitol. Therefore,
AKR1B10 has a role in the extra glucose handling associated with diabetes mellitus and
could also serve as target for drug treatments. The consequences of activation of
AKR1B10 hasn’t been fully established in diabetic nephropathy however one can
postulate there would be an increase in cellular damage due to oxidative and osmotic
stress that contributes to the progression of diabetic nephropathy.
Exposure to Cadmium Toxicity Induced AKR1B10 Expression
AKR1B10 is the least understood and studied aldose reductase isoform such that
there could be other factors that may lead to the activation of this enzyme. Results from a
global microarray analysis conducted on HPT cells exposed acutely and chronically to
cadmium showed an induction of AKR1B10 (Garrett et al., 2013, 2011). Results from the
present study have confirmed the findings from the global microarray data that acute and
chronic exposures to cadmium toxicity significantly induced AKR1B10 expression more
so than AKR1B1 expression. Prolong exposures to cadmium toxicity is capable of
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inducing several detrimental health effects. This is due to the fact cadmium is a
nephrotoxicant and has a long-half such that it easily accumulates within the proximal
tubule cell promoting damage, a hallmark signature of cadmium induced toxicity (Garrett
et al., 2011; Satarug, Garrett, Sens, & Sens, 2009).
Although there are little to no studies that can support the findings of activation of
the polyol pathway by cadmium toxicity, this study can bring forth a new area of research
for understanding the involvement of environmental toxicants in contributing to the
disease progression of diabetic nephropathy.
Cadmium Toxicity has a Role in Progression of Diabetes Mellitus
Epidemiological studies involving the long-term effects of cadmium exposures in
the human population have educated the not only researchers and health professionals but
also the general public about the adverse health effects that could occur if cadmium
exposure is not limited. Some early studies from Japan recognized a correlation between
cadmium exposures and increased incidence of kidney diseases and osteomalacia known
as “itai-itai” diseases (AOSHIMA, 2017; EMMERSON, 1970)
There have been other epidemiological studies that showed exposures to cadmium
toxicity increased the risk for diabetes mellitus however if the exposure was limited or
completely eliminated that risk for the onset of diabetes mellitus was minute
((Swaddiwudhipong et al., 2012, 2015; Tinkov et al., 2017).
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In light of the increasing evidence and support for the role of cadmium toxicity
and the onset or progression of diabetic mellitus this current study also supports this link.
Results have shown cadmium toxicity induces AKR1B10 expression and the same trend
is seen in a combined exposure of both cadmium and hyperglycemia. Although the
effects are not additive, both cadmium and hyperglycemia are inducing damage
synergistically through the activation of AKR1B10. Therefore it can be postulated that
AKR1B10 can be a marker for cadmium induced toxicity in relation to the disease
progression of diabetic nephropathy.
Role of Oxidative Stress in Diabetic Nephropathy
Activation of the polyol pathway by hyperglycemic events has been shown to
cause oxidative and osmotic stress that leads to the onset of complications of diabetic
nephropathy. When the polyol pathway is activated it promotes to oxidative and osmotic
stress in three ways; 1) decreased availability of NADPH for usage by glutathione
reductase which reduces glutathione disulfide to glutathionine protecting against reactive
oxygen species, 2) increased accumulation of intracellular sorbitol and 3) increased
production of reactive oxygen species (M Brownlee, 2001; Burg, 1988; Srivastava et al.,
2005; Tang & Lai, 2012). However results from this study also show hyperglycemic
conditions induce the expression of TXNIP.
TXNIP contributes to oxidative stress and damage by inihibiting the activity of
thioredoxin (Singh, 2013). Thioredoxin acts as an antioxidant utilizing NADPH to reduce
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reactive oxygen species in physiological conditions. However in state of hyperglycemia
thioredoxin is inhibited in two ways; 1) binding of TXNIP to the catalytic site and 2)
limited availability of NADPH. Results from the global microarray analysis on HPT cells
exposed and passaged in glucose for 24 days (P3) showed induction of TXNIP where
expression levels were confirmed by qPCR and western blot techniques. Since the aldose
reductase enzymes utilize NADPH for their reducing properties it could be argued that
activation of the aldose reductase contributes to inhibition of thioredoxin promoting an
increased accumulation of reactive oxygen species.
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Chapter V
Conclusions/ Future Directions
Diabetic nephropathy is a complicated disease where current treatments aim to
prevent the disease progression into renal fibrosis but are unable to do so. This study has
shown the complexities of the disease in primary and immortalized proximal tubule cell
model systems. Primary and immortalized proximal tubule cell model systems have
shown to have different biological responses to exposures to hyperglycemia.
The primary or immortalized cell model system’s response to hyperglycemia has
some variation as evident in the data of the polyol pathway enzymes. Primary HPT cells
have shown an induction of aldose reductase enzymes, AKR1B1 and AKR1B10, whereas
the RPTEC/TERT1 (ATCC CRL-4031) cells have shown a little to no induction of the
same enzymes. Activation of the aldose reductase enzymes have also led to an
intracellular sorbitol accumulation in primary HPT cells but not in RPTEC/TERT1
(ATCC CRL-4031), another major difference between these cell model systems.
When attempting to understand human diseases it is best to start with the best
model system and correct exposures of the toxicants being studied. For this project,
having access to primary kidney cells have set this study apart from those that do not
have access. This is because the elicited response should be almost similar to what is seen
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in the whole organ. However it also best to ensure the cells used maintain their
physiological properties.
The proximal tubule cells utilized in this study did not express key glucose
transporters. Therefore, these glucose transporters should be transfected in the kidney
cells and the study be reinvestigated although the lack of expression of these transporters
did not have an effect on the glucose utilization by these kidney cells.
All in all this study sheds some light into possible avenues that could be
investigated further to determine if the alternative isoform of aldose reductase, AKR1B10
can also serve as a biomarker for the disease progression of diabetic nephropathy.
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CHAPTER II
Abstract
Renal fibrosis is a major complication associated with the disease progression of
diabetic nephropathy (DN) to end-stage renal disease (ESRD), where prolong exposure to
hyperglycemia induces damage to proximal tubule cells of the kidney. Since progression
to ESRD correlates to pathological changes in the tubular segments of the kidney, the
effects of hyperglycemia in the proximal tubule portion of the nephron may be
particularly relevant to the progression of DN. Epithelial to mesenchymal transition
(EMT) of proximal tubule cells may play a role in the disease manifestation and
progression. The goal of this study was to characterize the pathological changes that
occur in human proximal tubule (HPT) cells exposed to hyperglycemia. For this purpose,
cells were exposed to one of the following treatments; 5.5 (control), 7.5, 11, or 16 mM
glucose concentrations for 8 days then consecutively subcultured for two more passages.
Real-time PCR and western blot analysis was used to measure the expression levels of
CDH2 and CDH1 at the mRNA and protein levels, respectively. Exposures to
hyperglycemia induced morphological changes and stimulated a significant induction of
CDH2 in HPT cells; however, exposure had no effect on CDH1 expression.
Hyperglycemia also induced the expression of SNAI1 at the mRNA level. The data from
the current study suggests hyperglycemic induced damage of the proximal tubule in the
kidney during the development of DN occurs through an EMT phenomenon.
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Introduction
There are several complications associated with diabetic nephropathy. One
process that seems to be the most daunting is the onset of fibrosis. Renal fibrosis is an
inevitable consequence that is seen in progressive chronic kidney diseases which occurs
when the kidney is no longer able to regenerate to heal itself. Evidence of fibrosis (or
scarring) leads to the loss of renal function eventually progressing into end-stage renal
disease. At this point, the only form of treatment is to have the patient undergo renal
dialysis or transplantation which is a major cost burden (Zeisberg & Kalluri, 2004)
Renal fibrosis is characterized as an excessive deposition of extracellular matrix
(ECM) in the tubulointerstitium, glomerulus, and vasculature (Zhou & Liu, n.d.).
Although the mechanism behind the irreversible damage is least understood, a common
denominator exists regardless of the primary cause which is the activation of
myofibroblasts. Activation of myofibroblasts occurs when the wound healing process is
initially turned on in response to mediators such as cytokines or growth factors produced
by injured resident epithelial cells (Efstratiadis, Divani, Katsioulis, & Vergoulas, 2009)
however fibrosis occurs when this process is continuous for long periods of time.
Early studies regarding renal fibrosis has been extensively focused on glomerular
cells (Danne, Spiro, & Spiro, 1993; D. Wang et al., 2015) because it was believed
damage to this region of the kidney would be the driving force for other complications
associated with diabetic nephropathy. However within the past decade of kidney fibrosis
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investigations, researchers have begun to appreciate tubulointerstitium damage also
contributes to the severity of the disease but also serve as a predictor of progression.
There are various cellular components contributing to the onset of renal fibrosis.
All cell types within the kidney are known to participate in the pathogenesis of renal
fibrosis however it is widely accepted the fibroblasts/myofibroblasts are the main cell
type responsible for accumulation of interstitial extra-cellular matrix (Carew, Wang, &
Kantharidis, 2012a; Efstratiadis et al., 2009; A.M. El Nahas, Muchaneta-Kubara,
Essaway, & Soylemezoglu, 1997). Activated fibroblasts are recognized by their
production of α smooth muscle actin (αSMA) (Hewitson, 2012; Zhou & Liu, n.d.),
however the source behind fibroblast activation or the origin of these cells is least
understood.
After several theories and speculations, a study characterizing the differences
between fibroblasts and epithelium found one gene is active in the promoter region of
fibroblasts but not epithelium. This gene came to be known as fibroblast specific protein
1 (FSP1) and is observed in injured regions of the tubular sections of the kidney
undergoing fibrosis, indicating tubular epithelial cells were converting to fibroblast in
response to injury (Strutz et al., 1995). This process of resident epithelial cells converting
into cells with characteristics of fibroblasts is known as epithelial to mesenchymal
transition (EMT).
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There are three types of epithelial to mesenchymal transition processes. Type 1
epithelial to mesenchymal transition occurs during organogenesis where immature
mesenchymal cells give rise to the mature epithelium. Type 2 epithelial to mesenchymal
transition occurs during the tissue repair process such as fibrosis, resulting in
myofibroblasts formation from resident epithelium to heal the injured regions of the
tissue. Type 3 epithelial to mesenchymal transition results in malignant cells having the
ability to metastasize and invade nearby tissue (Figure 2.1.1) (Tennakoon, Izawa,
Kuwamura, & Yamate, 2015).

Figure 2.1. Types of epithelial to mesenchymal transition processes. Adapted from
Zeisberg and Neilson, 2009.
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Tubular epithelial to mesenchymal transition is defined as the process where
resident renal epithelial cells lose their epithelial characteristics and obtain features of
mesenchyme (Zhou & Liu, n.d.). Epithelial cells are derived from the metanephric
mesenchyme in the reverse process of epithelial to mesenchymal transition, mesenchymal
to epithelial transition (MET) (Hay & Zuk, 1995). During homeostasis, renal epithelial
cells have distinct features that allow them to maintain the tissue’s organization. For
instance, renal epithelium has apical and basolateral surfaces that are easily
distinguishable from each other. The apical membrane is lined with a brush border that
helps to facilitate the maximal reabsorption of nutrients. The polarity of the epithelium is
regulated by adherens junctions and tight junctions.
Adherens junctions are composed primarily of E-cadherin (CDH1) and maintain
cell integrity by interacting with other E-cadherin proteins on neighboring cells
(Gumbiner, 2005; Yonemura, Itoh, Nagafuchi, & Tsukita, 1995). Tight junctions have
two primary proteins, occludins and claudins with each having separate roles in
maintaining the tight junction between cells (Hartsock & Nelson, 2008). All these
proteins have a profound role in maintaining organization of the cell but when there is
damage to these proteins, the epithelial cell organization is compromised.
The hallmark of epithelial to mesenchymal transition is the loss of E-cadherin
from the adherens junctions resulting in a dramatic remodeling of the cytoskeleton
resulting in a loss of adhesion and polarity and an increase in N-cadherin (CDH2)
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expression, a phenomenon called the cadherin switch (Tennakoon et al., 2015). Along
with the induction of cytoskeletal markers such as α-SMA, vimentin, fibroblast specific
protein -1 and β-catenin, these markers have been studied in context of Type 2 epithelial
to mesenchymal transition occurring in injured renal epithelial cells (Zeisberg & Neilson,
2009).
Hypothesis/ Rationale
Primary and immortalized proximal tubule cells continuously exposed and
passaged in hyperglycemia experienced a morphology change from a more cuboidal to an
elongated shape. Because this characteristic is evident of an EMT process, it would be
suggested EMT markers such as N/E-Cadherin, vimentin, fibronectin to name a few will
be induced in HPT cells in response to exposure and passaging in hyperglycemic
conditions.
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CHAPTER II.II
Methods
RNA isolation and RT-qPCR
Total RNA was purified from cultures of HPT or RPTEC/TERT1 (ATCC CRL4031) cells utilizing TRI Reagent (Molecular Research Center, Inc.) and quantified by
spectrophotometry (Nanodrop). 100 ng of total RNA was subjected to cDNA synthesis
using the iScript cDNA synthesis kit (Bio-Rad) for a final volume of 20 μL. Gene
expression was measured with real-time reverse transcription polymerase chain reaction
(RT-PCR) using primers of interest (see Table 1.2.1). Real time PCR was performed
using SYBR Green (Bio-Rad) with 2 μL cDNA and .2 μM primers in a final volume of
20 μL in the CFX96 Touch Real-Time detection system (Bio-Rad). SYBR Green
fluorescence was used to monitor the amplification of the reaction and further analyzed
by interpolation from a standard curve.

Gene
ACTA2
CDH1
CDH2
OCLN
Snail1
TGFB1
Twist
Vimentin

Company
BioRad
BioRad
BioRad
BioRad
BioRad
BIORAD
BioRad
BioRad
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Catalog No.
qHsaCID0013300
qHsaCED0042076
qHsaCID0015189
qHsaCED0038290
qHsaCED0038290
qHsaCID0017026
qHsaCED0043959
qHsaCID0012604

Table 2.2.1 Primer Information

Protein Isolation
For the glucose studies, total protein was isolated from HPT cells using a 2%
Sodium Dodecyl Sulfate (SDS) lysis buffer containing 50 mM Tris-HCL, pH 6.8 with
1% protease inhibitor cocktail (Sigma-Aldrich). Cell pellets were homogenized in the
lysis buffer, boiled for 10 minutes and subjected to DNA shearing by sonication. Protein
concentration was determined by BCA assay (Pierce). Samples were stored at -80ºC in
100 mM dithiothreitol.
For the cadmium and glucose studies with RPTEC/TERT1 (ATCC CRL-4031)
cells, total protein was isolated from the HPT and RPTEC/TERT1 (ATCC CRL-4031)
cells using a RIPA lysis buffer containing protease inhibitors, PMSF, and sodium
orthovandate (Santa Cruz). Cell pellets were homogenized in cold RIPA lysis buffer at a
1:2 w/v ratio and incubated on ice, with orbital shaking for 30 minutes. The samples were
then sonicated and centrifuged at 10,000g for 10 minutes at 4°C. The supernatant was
collected in cold, separate tubes and subjected to BCA assay (Pierce) for protein
quantification and stored -80ºC.
Western Blot Analysis
Protein expression was measured by western blot techniques. Twenty µg protein
was separated by SDS-Page using the TGX AnyKd SDS polyacrylamide gel (Bio-Rad).
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Samples contained equal amounts of protein and Laemmli buffer (Bio-Rad) containing βmercaptoethanol. The samples were then boiled for 5 minutes at 95ºC to reduce protein.
Once samples were back to room temperature, they were loaded into the gel. Proteins
were then transferred to a .2 µm PVDF membrane using a Trans-blot Turbo transfer
apparatus (Bio-Rad). After transfer, the membranes were blocked with 5% nonfat dry
milk in TBS-T for 90 minutes. Blots were incubated in 4ºC in the primary antibodies
overnight on an orbital shaker. Table 1.2.1 has a list of all antibodies.
Antibody Name

Mw (kDa)

Dilution

Species

Company

Catalog No.

ACTA2

42

1:1000

Rabbit

Abcam

Ab5694

ACTB

42

1:3000

Mouse

Abcam

Ab8226

CDH1

120

Rabbit

Santa-Cruz

Sc-7870

CDH2

137

Mouse

Invitrogen

333900

1:1000

Table 2.2.2 Antibody source.
Transepithelial Resistance
Transepithelial resistance was measured in HPT or RPTEC/TERT1 (ATCC CRL4031) cells exposed to hyperglycemia. HPT or RPTEC/TERT1 (ATCC CRL-4031) cells
were seeded at a 2:1 ratio in triplicate onto a 24 mm-diameter cellulose ester membrane
inserts (Corning). The inserts were then placed into six-well plates. On the third day postseed, HPT or RPTEC/TERT1 (ATCC CRL-4031) cells started 5.5, 7.5, 11, 16 mM
glucose treatments. On the first day of the glucose treatments, transepithelial resistance
(TER) was measured every day for twelve days with the EVOM Epithelial Voltohmmeter
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(World Precision Instruments, Sarasota, FL) with a STX2 electrode according to
manufacturer’s instructions. The resistance of a filter containing control medium but with
no cells was subtracted from filters containing a monolayer of cells. The corrected
resistance values were multiplied by the surface area of the filter (available for growth) to
get a final unit of area resistance. Three sets of four readings were taken at four different
quadrants on each filter. The morphology of the monolayer was monitored for dome
formation in a separate 6-well plate without inserts. The experiment was repeated twice
and the final replicate recordings were reported as the ±SEM.
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CHAPTER II.III
Results
HPT Cells Passaged in Glucose Exhibit a Morphology Change
HPT cells continuously exposed and passaged in glucose for 24 days (P3) had
showed signs of morphology change. These changes were captured using a light/dark
phase contrast microscope. In the first 8 days (P1) of exposure, the HPT cells are still
forming domes (outlined regions) and are cuboidal in shape (Figure 2.3.1). However, as
these cells are continuously exposed and passaged in hyperglycemic conditions, they
undergo a morphology change. These cells become more elongated (Figure 2.3.2) and not
as cuboidal in shape as seen in the first passage (Figure 2.3.1).
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Figure 2.3.1 Light Level Morphology of HPT cells Exposed to Glucose for 8-Days.
Human proximal tubule cells exposed to 5.5 mM (control), 7.5 mM, 11 mM, and 16 mM
glucose for 8 days. Highlighted boxed represent regions of dome formation.
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Figure 2.3.2 Light level morphology of HPT cells exposed and passaged in Glucose
for 24-days. Human proximal tubule cells exposed and passaged in 5.5 mM (control),
7.5 mM, 11 mM, or 16 mM glucose for 24 days (P3). Black arrows represent regions of
irregular morphology.

CDH2 Expression is Induced in HPT Cell Passaged in Glucose
Evidence from the morphology changes in response to being exposed and
passaged in high concentrations of glucose is suggestive of an EMT process. This process
is characterized by the E-Cadherin (CDH1) and N-Cadherin (CDH2) switch however
there are other markers that when induced could indicate an EMT process occurring.
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These other markers are: fibronectin (FN1), vimentin (VIM), smooth-muscle actin
(ACTA2) and transcription factors: snail (SNAI1), slug (SNAI2), twist (1/2). Measured the
expression of CDH1 and CDH2 in HPT cells exposed and passaged in glucose.
The expression of CDH1 is induced in the first 8 days of exposure by 16
mM glucose but then no induction in 16 day (P2) exposure and is back to being induced
in 24 days (P3) exposure by 16 mM (Figure 2.3.3 A). On the other hand, CDH2
expression in continuously induced by 16 mM glucose exposure across all three passages,
with a 6 to 7-fold induction in the 24 day (P3) exposure (Figure 2.3.3 B). The induced
expression is translated into the protein analysis as well.
ACTA2 expression levels were shown to be affected by the hyperglycemic
conditions. In the first 8 days (P1) of exposure, there is a 2-fold induction of ACTA2 by
16 mM glucose to a 10 to 15- fold induction by 16 days of exposure (P2). After 24 days
(P3) of being in hyperglycemic conditions, there is steady and significant induction of
ACTA2 (Figure 2.3.4). However both VIM and FN1 expression were not induced in
HPT cells exposed and passaged in 5.5, 7.5, 11, 16 mM glucose (Figure 2.3.5 A, B).
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Figure 2.3.3 CDH1 and CDH2 expression in HPT cells exposed and passaged in
glucose. RT-PCR and protein analysis of CDH1 (A) and CDH2 (B) in HPT cells
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change
normalized to ACTB. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01,
***p<0.001
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Figure 2.3.4 ACTA2 mRNA expression in HPT cells exposed and passaged in
glucose. RT-PCR and protein analysis of ACTA2 in HPT cells exposed and passaged in
5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change normalized to ACTB. RTPCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001Junctions
Proteins are not Affected by Glucose Toxicity
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Figure 2.3.5 VIM and FN1 mRNA expression in HPT cells exposed and passaged in
glucose. RT-PCR and protein analysis of VIM (A) and FN1 (B) in HPT cells exposed
and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change normalized
to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.00

All of aforementioned genes are turned on by certain transcription factors. SNAI1
and TWIST1 are common transcription factors that will induced an EMT response.
Expressions of both SNAI1 and TWIST1 were measured in HPT cells exposed and
passaged in glucose. SNAI1 expression is induced ~3-fold in the first 8 day (P1)
exposure to 16 mM glucose (Figure 2.3.6 A). On the other hand, TWIST1 expression is
induced 10 - 20–fold in HPT cells exposed to hyperglycemic condition for 16 days (P2)
or longer (P3) (mRNA data only) (Figure 2.3.6 B). There is no western analysis for
TWIST1 protein expression due to antibody problems.
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Figure 2.3.6 SNAI1 and TWIST expression in HPT cells exposed and passaged in
glucose. RT-PCR and protein analysis of SNAI1 (A) and TWIST (B) in HPT cells
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change
normalized to ACTB. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01,
***p<0.001
Junctional Proteins are not Affected by Exposures to Hyperglycemia
Claudin and occludin proteins are found at the intercellular junctional complexes.
These proteins help to establish tight junctions and maintain the stability and barrier
properties of tight junctions. Since passaging of HPT cells in high levels of glucose
causes morphology changes, it would be possible that glucose could affect the expression
of these tight junction proteins. However data from this study has shown HPT cells
exposed and passaged in glucose had no effect on the following tight junction proteins;
claudins-1/2, (Figure 2.3.7 A, B) and occludin-1 (Figure 2.3.8).
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Figure 2.3.7 CLDN1 and CLDN2 mRNA expression in HPT cells exposed and
passaged in glucose. RT-PCR and protein analysis of CLDN1 (A) and CLDN2 (B) in
HPT cells exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold
change normalized to control. RT-PCR results represent ±SEM of triplicate. *p<0.05,
**p<0.01, ***p<0.001
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Figure 2.3.8 OCLN1 mRNA expression in HPT cells exposed and passaged in
glucose. RT-PCR and protein analysis of OCLN1 in HPT cells exposed and passaged in
5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change normalized to control. RTPCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001

Gap junction proteins, GJB1 and GJB2, expression was also measured to
determine if hyperglycemia had altered their expression. Within the first passage in
glucose, both GJB1 and GJB2 expression was induced in response to increasing glucose
concentrations (Figure 2.3.9 A,B). GJB1 expression was also induced in HPT cells
exposed and passaged in glucose for 24 days (P3) however (Figure 2.3.9 A), GJB2 was
not induced in the latter passages (Figure 2.3.9 B).
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Figure 2.3.9 GJB1 and GJB2 mRNA expression in HPT cells exposed and passaged
in glucose. RT-PCR and protein analysis of GJB1 (A) and GJB2 (B) in HPT cells
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change
normalized to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01,
***p<0.001
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CHAPTER II.IV
Discussion
The present study establishes that HPT cells in a prolonged hyperglycemic
environment undergo a partial EMT process. Chronic kidney disease is a global epidemic
and becoming a worldwide healthcare burden not only to the health care physicians but
more importantly to the patient. Progressive injury to the kidneys results in renal fibrosis
which is the final pathway for all chronic kidney diseases and the point at which
irreversible damage is prevalent. At this state, there are no therapeutic treatments other
than kidney transplantation or life-long dialysis treatments therefore understanding the
mechanisms behind the development of renal fibrosis will help to develop therapeutic
targets for inhibiting the disease progression of diabetic nephropathy into renal fibrotic
state.
The present study provides an insight into a potential mechanism of the gradual
damaging process that may occur during the disease transition of diabetic nephropathy to
a fibrotic state. Several studies have suggested dedifferentiation of renal epithelial cells
through type 2- EMT process has a role in the onset of fibrosis. EMT is a biological
process that has a major role in developmental and pathological properties such as the
loss of apical-basolateral polarity, loss of cell to cell contact, and reorganization of
cytoskeletal actin (Expósito-Villén, E. Aránega, & Franco, 2018; Kizu, Medici, &
Kalluri, 2009). These genetic alterations promotes the transition of epithelial cells into
cells with mesenchymal features which is commonly characterized by an induction of N119

cadherin and a repression of E-cadherin (Iwano et al., 2002; Lovisa et al., 2015; Zeisberg
& Kalluri, 2013; Zeisberg & Neilson, 2009).
Results from this study suggest there is an EMT process occurring through the
activation of CDH2, SNAI1, ACTA2, TWIST genes in response to exposures to
hyperglycemica. Although there were several epithelial markers that had no change in
expression such as CDH1, Claudin-1/2, occludin, GJB-1/2, these cells may have been
caught in the early stages of initiating a mesenchymal state. This partial transition is also
depicted in the morphology images HPT cells exposed and passaged in hyperglycemia
where some cells appear to be “elongated” in shape whereas others are more “cuboidal”.
There is a lack of support in the literature for the evidence of the EMT
phenomenon occurring in only some of the cells because researchers in this area of the
field believe the EMT process is an all-or-none phenomenon. In a study conducted by
Grande et al., 2015, had shown activation of SNAI1 in mouse renal epithelial cells
promotes signals for myofibroblast differentiation without inducing the myofibroblast
population (Grande et al., 2015) supporting the idea of a “partial” EMT process. In
another study where immortalized proximal tubule cells were exposed to 25 mM glucose
for 48 hours, showed appreciable high expression of vimentin and α-smooth muscle actin
and repressed expression of e-cadherin (Liu et al., 2016).
Although there have been several studies investigating EMT processes and its role
in renal fibrosis, there are still remains several controversies regarding if EMT is the
120

driving force for the development of fibroblasts. However, as researchers continue to
investigate the relationship between EMT and renal fibrosis, there will be a possible
therapeutic approach to prevent renal fibrosis.
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